mosunetuzumab-axgb bulk supplier for pharma manufacturers

Mosunetuzumab-Axgb 1 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 1 mg/mL

Reference Brands: Lunsumio (USA/EU)

Mosunetuzumab-axgb is a bispecific CD20-directed CD3 T-cell engager. It binds CD20 on B-cells and CD3 on T-cells, bringing T-cells into proximity with cancerous B-cells so the immune system can attack and destroy them. It is used to treat adult patients with relapsed or refractory Follicular Lymphoma (a type of non-Hodgkin B-cell lymphoma) after they have had at least two prior systemic therapies.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Mosunetuzumab-Axgb? List it or send an offer →

Product Description:

Mosunetuzumab links CD20 on a malignant B cell to CD3 on a T cell, forcing the T cell to kill a target it would otherwise ignore. It belongs to the same class as the other CD20 bispecifics but occupies a different clinical niche, because its toxicity profile is mild enough that treatment can start in an outpatient setting in many centres rather than requiring admission for the step-up doses.

It is used for relapsed or refractory follicular lymphoma after two or more prior systemic therapies, given intravenously for a fixed number of cycles, with treatment extended only in patients who have not reached complete response. The fixed duration matters in an indolent, relapsing disease where patients may otherwise face indefinite therapy. Cytokine release syndrome is common but usually low grade and confined to the first cycle. Neutropenia, infection, fatigue and headache occur, and hypogammaglobulinaemia may need immunoglobulin support.

Sourcing notes. Originator biologic under patent, supplied in vial strengths corresponding to the step-up and treatment doses — a course needs both. Cold chain at 2–8 degrees, protect from light, do not freeze or shake. Confirm that the treating centre has a cytokine release syndrome protocol.

How Mosunetuzumab-Axgb is supplied today, and licensing ahead of patent expiry

Mosunetuzumab-Axgb is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Mosunetuzumab-Axgb, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Mosunetuzumab-Axgb supply →

Back to Listing

Frequently Asked Questions

Mosunetuzumab-axgb is used to treat relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies.

Mosunetuzumab-axgb is a bispecific monoclonal antibody designed to bind both CD20 on B-cells and CD3 on T-cells, directing the immune system to destroy malignant B-cells.

The trade name is Lunsumio.

Lunsumio is manufactured by Genentech, a member of the Roche Group.

The generic name is mosunetuzumab-axgb.

The brand name is Lunsumio.

It is manufactured in the United States and Europe by Genentech/Roche.

Lunsumio (Mosunetuzumab) is developed and sold by Roche. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.